



BSI Standards Publication

**Nanotechnologies —
Determination of silver
nanoparticles potency by
release of muramic acid from
*Staphylococcus aureus***

National foreword

This Published Document is the UK implementation of ISO/TS 16550:2014.

The UK participation in its preparation was entrusted to Technical Committee NTI/1, Nanotechnologies.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2014.

Published by BSI Standards Limited 2014

ISBN 978 0 580 74491 4

ICS 07.030

Compliance with a British Standard cannot confer immunity from legal obligations.

This Published Document was published under the authority of the Standards Policy and Strategy Committee on 30 September 2014.

Amendments/corrigenda issued since publication

Date	Text affected
-------------	----------------------

**Nanotechnologies — Determination
of silver nanoparticles potency
by release of muramic acid from
*Staphylococcus aureus***

*Nanotechnologies — Détermination de l'efficacité des nanoparticules
d'argent par la libération de l'acide muramique du Staphylococcus
aureus*





COPYRIGHT PROTECTED DOCUMENT

© ISO 2014

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

	Page
Foreword	iv
Introduction	v
1 Scope	1
2 Terms and definitions	1
3 Symbols and abbreviated terms	3
4 Principles	3
5 Sample preparation for the determination of MA	4
5.1 Bacterial growth and AgNP treatment.....	4
5.2 Hydrolysis of cell wall.....	6
5.3 Derivatization of cell wall.....	6
5.4 Gas chromatography-mass spectrometry instrumentation.....	6
6 Data analysis and results interpretations	7
7 The test method for silver nanoparticle sample	8
Annex A (informative) Gas chromatography-mass spectrometry	9
Annex B (informative) Internal standard	10
Annex C (informative) Preparation of laboratory-prepared silver nanoparticles reference materials	11
Annex D (informative) Silver nanoparticle suspension preparation	12
Annex E (informative) Treatment control conditions; positive, negative, and bacterial suitability controls	13
Bibliography	14

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the WTO principles in the Technical Barriers to Trade (TBT) see the following URL: Foreword - Supplementary information.

The committee responsible for this document is ISO/TC 229, *Nanotechnologies*.

Introduction

The antimicrobial properties of silver nanoparticles (AgNPs) are being increasingly utilized in consumer products. It has been widely used for development of many biological and pharmaceutical processes, products, and applications such as coating material for medical devices, orthopaedic or dental graft materials, topical aids for wound repair, clothing, underwear and socks, textile products, and even washing machines.^[1] Industries are producing wide varieties of AgNPs as an antibacterial agents with different physical properties and with little low concern to their side effects. Moreover, there is a risk of enhanced bioavailability of the nanoparticles in the different media^{[2][3]} which might have impact on the beneficial soil flora, plants, animals, and humans. From this point of view, the potency of AgNPs should be evaluated and classified according to its final biological activities.

This Technical Specification does not describe use of this Technical Specification to evaluate what properties of silver nanomaterial are to be assessed.

Nanotechnologies — Determination of silver nanoparticles potency by release of muramic acid from *Staphylococcus aureus*

1 Scope

This Technical Specification provides a test method for evaluating potency of silver nanoparticles to cell wall degradation of *Staphylococcus aureus* and muramic acid release as quantified by a gas chromatography-mass spectrometry (GC-MS).

2 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

2.1

antibacterial activity

property of compound or substance that kills (bactericidal) or slows down (bacteriostatic) the growth of bacteria

2.2

dynamic light scattering

photon correlation spectroscopy

DLS

technique in physics that can be used to determine the size distribution profile of small particles in suspension or polymers in solution

2.3

gas chromatography–mass spectrometry

GC-MS

method that combines the features of gas-liquid chromatography and mass spectrometry to qualitatively and quantitatively analyse volatile compounds within a test sample ([Annex A](#))

2.4

Gram positive bacteria

bacteria that are stained/resistant to bleaching by organic solvent during Gram staining

2.5

internal standard

compound of known concentration added to a sample to facilitate the qualitative identification and/or quantitative determination of the sample components ([Annex B](#))

[SOURCE: ISO 20752, 3.2]

2.6

limit of detection

LOD

minimum amount or concentration of the analyte in a test sample which can be detected reliably, but not necessarily quantified, as demonstrated by a collaborative trial or other appropriate validation

[SOURCE: ISO 8196-1, 3.4.3]

2.7
limit of quantification
LOQ

lowest concentration of target in a test sample that can be quantitatively determined with acceptable level of precision and accuracy under the experimental conditions specified in the method, as demonstrated by a collaborative trial or other validation

[SOURCE: ISO/TS 15216-1, 3.18]

2.8
linear dynamic range
LDR

regression curve of Y on X is a straight line and the regression is called LDR

[SOURCE: ISO 3534-1, 1.34]

Note 1 to entry: The coefficient of linear regression of Y on X is the coefficient of x (slope) in the equation of the regression line.

2.9
muramic acid

form of sugar amide which chemically is the ether conjugate between lactic acid and glucosamine. It occurs naturally as an N-acetyl derivative in peptidoglycan[8]

Note 1 to entry: 3-O- α -carboxyethyl-D-glucosamine.

Note 2 to entry: See [Figure 1 b](#)).




Figure 1 — Structure of a) peptidoglycan layer, b) muramic acid

2.10
peptidoglycan
(murein, PGN)

polymer consisting of sugars and amino acids that forms a mesh-like layer outside the plasma membrane of bacteria forming the cell wall

Note 1 to entry: The peptidoglycan is a specific and essential element in the cell wall of almost all bacteria. Its amount in cell walls of Gram positives is substantial, see [Figure 1 a](#)).[3]

2.11
silver nanoparticle potency

reaction of silver nanoparticles with a bacterium's cell wall as measured indirectly by muramic acid release

2.12

Staphylococcus aureus

S. aureus

facultative anaerobic, Gram positive coccus, coagulase positive, which appears as grape-like clusters when viewed through a microscope, able to grow in a hypersaline medium with manitol as the sole carbon source producing a yellow pigment

2.13

trace

µg/ml concentration or lower

2.14

transmission electron microscopy

TEM

instrument that produces magnified images or diffraction patterns of the sample by an electron beam which passes through the sample and interacts with it

[SOURCE: ISO/TS 10797, 3.8]

2.15

ultraviolet visible spectroscopy

UV-Vis

absorption spectroscopy or reflectance spectroscopy in the ultraviolet-visible spectral region

Note 1 to entry: This means it uses light in the visible and adjacent [near-UV and near-infrared (NIR)] ranges.

2.16

x-ray power diffraction

XRD

method in which the elastically scattered intensity of X-rays is measured

[SOURCE: ISO/TS 80004-6, 3.2.4]

3 Symbols and abbreviated terms

AgNP	Silver Nanoparticle
MA	Muramic Acid
MHB	Mueller Hinton Broth
OD	Optical Density at 600 nm
SIM	Selected Ion Monitoring

4 Principles

PGN is a specific and essential component in the cell wall of bacteria.^[8] Its main structural features are linear glycan strands cross-linked by short peptides. The glycan strands are made up of alternating N-acetylglucosamine and N-acetylmuramic acid, MA, residues linked by β -1→4 bonds, and the peptide chain is composed of L-alanine, D-glutamine, L-lysine, and D-alanine in the case of *S. aureus* (see [Figure 1 a](#)).^{[8][9]} It has been shown that AgNPs will damage the bacterial cell wall and production of the PGN fragments, leading to increased MA concentration in the culture media.^{[8][12]}

AgNPs as the active entity of colloidal AgNPs could have various sizes, surface features, shapes, zeta potential, and concentrations in different trade products. The activity of AgNPs depends on the mentioned characteristics, which could have synergistic or antagonistic cross-effects.^[12] Distinguishing among the effects caused by each of these parameters would require the preparation of a large number of samples

and use of a great variety of instrumentations. Subsequently, monitoring the concentration of MA is one indicator of the effects of these characteristics on AgNPs potency.^{[12][13][14][15][16]}

This Technical Specification utilizes a very sensitive measure of a single analyte, muramic acid as an indirect measure of a single mode of action, cell wall degradation. This method's sensitivity allows for muramic acid quantification below the minimum inhibitory concentration (MIC).^{[17][18]} However, the effect of silver nanoparticles detected through muramic acid liberation does not indicate lethality or cessation of cell growth.

Furthermore, the method relies on a single laboratory synthesized calibration sample to establish a dose response curve for later use with a widely accepted reference. Nanoparticles possess a particle-chemical duality; in that, the particle can be a reservoir for chemical release by dissolution processes. The protocol described in this Technical Specification does not offer information about broad spectrum bactericidal action of silver nanoparticles.

An effect on *Staphylococcus aureus* cannot be predictive for other Gram positive organisms and would not be expected to apply to Gram negative organisms due to the profound structural difference between the two cell wall types with respect to peptidoglycan proportion. Thus, this is not a comprehensive survey of nanoparticle effects upon bacteria.

In light of these considerations, characterization data for the laboratory-prepared silver nanoparticle calibration and system validation reference material can be found in [Annex C](#).

5 Sample preparation for the determination of MA

5.1 Bacterial growth and AgNP treatment

5.1.1 Principle of the test method

Fresh broth cultures of *S. aureus* ATCC 25923, in the OD₆₀₀, approximately 0,45 to 0,5 (CFU/ml approximately $1 - 2 \times 10^9$ or the mid-logarithmic phase of growth) phase are treated with AgNPs and incubated for 18 h at 37 °C with shaking (180 rpm to 200 rpm). Afterwards, the culture is clarified with centrifugation and filtration prior to being dried using rotary evaporator and freeze drier instruments. In the next step, muramic acid concentration will be determined by using method described in this Technical Specification. It is essential that the cultures used in the experiment contain a high titre of viable bacteria. In each experiment, the titre at least should be demonstrated either from historical control data on growth curves and through the determination of OD₆₀₀ within a time range that could ensure the high titre of viable cells (OD₆₀₀ approximately 0,45 to 0,5).

5.1.2 Description of the method

5.1.2.1 Materials

- *S. aureus* ATCC 25923
- MHB medium¹⁾

5.1.2.2 Test conditions

- 1) A fresh culture of bacterium should be prepared on nutrient agar (NA) plate, by striking of a single colony on the NA plate.
- 2) Triplicate flasks, each containing 25 ml sterile MHB medium (in 150 ml to 200 ml Erlenmeyer flasks) should be used for assay of each concentration of AgNPs.

1) MHB medium is available from Merck Co., Darmstadt, Germany. This information is given for the convenience of users of this document and does not constitute an endorsement by ISO of this product.

- 3) A pre-culture of bacterium should be prepared in the MHB medium about 2 h to 3 h before inoculation of Erlenmeyer flasks. A tube containing 5 ml MHB should be inoculated by a single colony of bacterium and be shaken at 37 °C to reach turbidity equal to 1 McFarland standard tube. For preparation of 20 ml of bacterial suspension 0,1 ml pre-cultured broth medium should be added to sterile 100-ml Erlenmeyer flask containing 20 ml MHB medium, and incubated at 37 °C to reach OD₆₀₀ approximately 0,45 to 0,5 (CFU/ml approximately 1-2 × 10⁹) or the mid-logarithmic phase of growth. This OD is recommended based on the experiments for drawing growth curve according to data obtained from OD₆₀₀ reading parallel to CFU counts determination. Under the sterile condition, the prepared bacterial suspension should be used based on [Table 1](#).
- 4) Cultures in the stationary phase should not be used.
- 5) The recommended culture temperature and rpm of shaking are 37 °C and 180 rpm to 200 rpm, respectively.

5.1.2.3 Solvent/vehicle

In the case of powdered AgNPs, the solvent/vehicle should not be suspected of chemical reaction with the test substance and bacteria. It is recommended that wherever possible, the use of an aqueous solvent/vehicle be considered first ([Annex D](#)).

5.1.2.4 Exposure concentrations

At least five different treatment conditions (according to the [Table 1](#)) of the test substance should be used.

5.1.2.5 Procedure

Culture of *S. aureus* ATCC 25923 should be performed in MHB medium based on the [5.1.2.2](#). Before the time of AgNPs treatment, a 20 ml MHB medium should be inoculated by 0,1 ml of pre-culture of the strain and incubated at 37 °C, 180 rpm to 200 rpm to reach OD₆₀₀ of about 0,45 to 0,5.

5.1.2.6 Treatment with test substance

Laboratory-prepared AgNP reference materials (see [Annex C](#)) and working AgNPs treatments should be done at different concentration levels. The treatments are explained in [Table 1](#) based on the volumes of the AgNPs colloidal suspensions, culture media, and bacterial suspensions in the final volume of 5 ml. In the case of powder samples, please refer to [Annex D](#).

Table 1 — AgNP treatment in concentration

No. sample	1 ^{a,c}	2	3	4	5
AgNPs ^b (ml)	0	0,05	0,25	0,5	1,25
Bacterial suspension (ml)	2,5	2,5	2,5	2,5	2,5
Medium (gram)/ D.W. (ml)	0,052 5/2,5	0,052 5/2,45	0,052 5/2,25	0,052 5/2,0	0,052 5/1,25

^a For the conditions of positive/negative controls, see [Annex E](#).

^b Colloidal/powder suspension ([Annex D](#)) of AgNPs.

^c For treatment #1, the amount of MHB powder needed for the preparation of medium is the same as recommended by manufacturer for preparation of routine (1X) MHB medium; and for the others, it should be prepared in such a way ensuring the equal amounts of nutrients in the final 5 ml volumes of all treatments. For this purpose for all treatment, 0,0525 g of medium powder should be dissolved in different amounts of distilled water (D.W.), and then be autoclaved before adding to each treatment. The amount of D.W. to be used is as follow: 2,5 ml for #1, 2,45 ml for #2, 2,25 ml for #3, 2,0 ml for # 4, 1,25 ml for #5, as indicated in [Table 1](#).

5.1.2.7 Incubation

All flasks in a given assay should be incubated at 37 °C for 18 h with shaking (180 rpm to 200 rpm). After the incubation period, culture should be centrifuged at 10 000 g, at 4 °C for 20 min. Thereafter, the supernatant should be filtered through 3 µm [Polytetrafluoroethylene (PTFE), Hydrophilic]. The filtrate should be concentrated to about 5 ml using rotary evaporator apparatus, fully dried using freeze dry apparatus at -50 °C and should be kept at -20 °C for subsequent analysis.

5.2 Hydrolysis of cell wall

The frozen supernatant, containing 1 mg of dried culture media, should be refluxed with 30 ml of 6 M HCl under N₂ gas for 21 h at 115 °C. After cooling, the hydrolysate should be filtered and completely dried by a rotary evaporator at 40 °C in vacuum. The dried residue should be dissolved in 20 ml H₂O and its pH should be set at about 6,6 M to 6,8 M by 0,4 M KOH. It should then be evaporated again by a rotary evaporator and finally 3 ml methanol (dried using MgSO₄) should be added to the residue and centrifuged for 10 min at 6 000 g. After removing the salt, it should be dried under dry air or N₂.^[11]

5.3 Derivatization of cell wall

In order to convert the MA into volatile state, with the dried sample, the aldonitrile derivatization method should be performed.^[9] A reagent containing 32 mg/ml hydroxylamine hydrochloride and 40 mg/ml 4-(dimethylamino) pyridine in pyridine-methanol (4:1 v/v) should be prepared. To 15 ml of this reagent, a 0,05 mg *myo*-inositol should be added. From the latter, a 0,3 ml aliquot should be added to a 3 mg of dried sample. After capping and shaking the vial manually for about 30 s, it should be heated for 30 min at 75 °C to 80 °C. The vial should then be cooled to room temperature, and then 1 ml acetic anhydride should be added. After capping and shaking the vial again, it should be reheated for 20 min. Thereafter, a 2 ml dichloromethane should be added in a continuous manner to the cooled solution. This product should be cleaned thoroughly before analysing with GC-MS by washing it three times with 1 M HCl and H₂O. Finally, the organic layer should be dried at 45 °C under N₂ gas and should then be dissolved in 200 µL dichloromethane.^[11]

5.4 Gas chromatography-mass spectrometry instrumentation

For evaluation of MA, a gas chromatograph equipped with a mass spectrometer is utilized. A non-polar column (30 m × 0,25 mm ID, 0,25 µm thickness) in the split ratio of 1:30 should be used. The temperature program should be set as follows.

- Hold the initial column temperature of 90 °C for a minute, then increase to 250 °C at the rate of 10 °C/min and hold at this temperature for 3 min.
- Put off the ion source ionization mode for 10 min, followed by the SIM method (for trace samples) for 10 min at the detection range of 50 m/z to 1 000 m/z.
- Adjust the ion source temperature at 200 °C.

To improve the precision of quantitative analysis, the internal standard (for example, *myo*-inositol) should be used. [Figure 2](#) represents the separation of MA and *myo*-inositol.




Figure 2 — GC-MS analysis of standard solutions a) chromatogram, b) spectrum of *myo*-inositol and c) muramic acid

6 Data analysis and results interpretations

A stock solution of MA (1 000 µg/ml) should be prepared as outlined earlier. The stock solution should be diluted to the final concentrations in the range of 1 µg/ml to 1 000 µg/ml of MA, including the *myo*-inositol, as an internal standard. The peak area of the *myo*-inositol (internal standard is used to modify the muramic acid peak area and omit the variation between injections. Each concentration should be analysed in three replicates. The modified MA peak areas are calculated using Formula 1.

$$\text{modified response} = \frac{\text{average values of MA areas}}{\text{average values of myo-inositol areas}} \quad (1)$$

The modified responses are plotted against the corresponding concentrations. The results are shown in [Table 2](#). The limit of detection (LOD) and limit of quantification (LOQ) should then be determined as modified responses giving rise to signal-to-noise ratios of 3 and 10, respectively. In order to estimate the LOD and LOQ of method, sample solution should be spotted three times, followed by the proposed method and the signal-to-noise ratio determined. The standard deviation of three replication of samples were ± 0,0128.

Table 2 — Validation and quantification of results

	Amount
LOD (µg/ml)	1
LOQ (µg/ml)	3,3
LDR (µg/ml)	3,3 to 1 000
Coefficient of regression (r ²)	0,9950

7 The test method for silver nanoparticle sample

The solutions of silver nanoparticles test sample suspension and working/reference silver nanoparticle ([Annex C](#)) should be prepared in different treatment levels ([Table 1](#)). The difference of muramic acid released by test sample of silver nanoparticle with respect to muramic acids released by reference silver nanoparticle shows potency of test sample. The acceptable level of potency is determined based on the agreement between the manufacturer and user. The negative control should contain the solvent/vehicle of the silver nanoparticle test sample.

Tandem mass spectrometry and selected ion monitoring methods can be used for increased sensitivity when muramic acid concentration is very low and sample medium is complex.

Annex A (informative)

Gas chromatography-mass spectrometry

- **Gas chromatography (GC):** separation of mixtures of compounds in their gaseous form; can be achieved by passing them in an inert gas, called the carrier gas (such as helium) through a column containing a stationary phase for which select for various components will have different affinities. The column is held in an oven at a carefully controlled constant/programmable temperature.
- **Mass spectrometry (MS):** an instrument which measures the ratio of mass to the number of charges of ions produced from elements and compounds. MS identifies substances by accelerating ions through a mass analyser, breaking the molecules into charged fragments, and detecting the difference between them.
- **Selected ion monitoring (SIM):** the selected ions are a characteristic of the target analyte. In a SIM, only a selected m/z value (or more) is/are detected. This has the potential to increase the overall sensitivity of the mass spectrometer response by avoiding the time spent, in scanned spectra, on areas of the mass range where no ions of interest will be found. SIM experiments can be performed using mass spectrometry (MS) or tandem mass spectrometry (MS/MS) instruments.
- **Tandem mass spectrometry:** it is also known as MS/MS or MS², involves multiple steps of mass spectrometry selection, with some form of fragmentation occurring in between the stages. Multiple stages of mass analysis separation can be accomplished with individual mass spectrometer elements separated in space or using a single mass spectrometer with the MS steps separated in time. This technique is used to improve the detection limit and to overcome the identification of trace analytes in complex mixtures.

Annex B **(informative)**

Internal standard

The method of internal standards is used to improve the precision of quantitative analysis. Internal standards are especially useful for analyses in which the quantity of sample is analysed, or for the instrument response which might vary slightly from run-to-run, for reasons that are difficult to control. Internal standards can then be used for calibration by plotting the ratio of the analyte signal to the internal standard signal as a function of the analyte concentration of the standards. This calibration is done to correct for the loss of analyte during sample preparation or sample inlet. The internal standard is a compound that is very similar, but not identical to the chemical species of interest in the samples, as the effects of sample preparation should, relative to the amount of each species, be the same for the signal from the internal standard as for the signal(s) from the species of interest in the ideal case.

Annex C (informative)

Preparation of laboratory-prepared silver nanoparticles reference materials

To prepare AgNP colloid, AgNO₃ (1,0 × 10⁻³ M) aqueous solution containing 0,1 % polyvinyl alcohol (PVA) as a surfactant should be reduced using a dropwise addition of 3-sodium citrate solution at near the boiling point (97 °C ± 0,5 °C). After 20 min, a yellowish gray suspension could be obtained. The optical properties of AgNPs should be evaluated using a UV-Vis spectrophotometer.^[12] In order to study their shape and morphology, TEM should be employed. Size of the prepared AgNPs should be studied using a DLS equipped with 632,8 nm HeNe-laser. The size measurement should be accomplished with respect to the UV absorption coefficient (ϵ) of the suspension at 632,8 nm and its refractive index (RI). The resulting nanoparticles should be purified by centrifugation at 16 000 g × 4 and washing with deionized water. Based on XRD study, the powder microcrystalline sample could be loaded into an aluminium sample holder that is rotated during data collection to improve particle statistics and to minimize preferred orientation effects. Diffraction data should be collected in the range of 1 to 80 (2 θ), on powder X-ray diffractometer equipped with a scintillation detector, secondary monochromator, and Cu K α 1 radiation ($\lambda = 1,5406 \text{ \AA}$). The particle size is in the range of 16 nm to 19 nm.^[12] Further information of physico-chemical characterization of sample and standard can be obtained according on ISO Technical Reports.^{[19][20]} DLS and UV/Vis physical measurements of the reference material stock solution should be performed before and after the time the AgNP reference material is used as a calibrant in the test method (e.g. >18 h). Statistical comparison of these size measurements establishes that the reference stock sample remained stable over that time of the treatment. These values should be recorded and used to set validated operating specifications. Ensuring that nanoparticle reference materials meet these specification during every experiment provides confidence in the comparability of day-to-day and laboratory-to-laboratory reference material preparations. The laboratory-prepared AgNP reference materials should be discarded after 24 h of preparation.

NOTE 1 This laboratory-prepared reference material is a colloidal, spherical nanoparticle. It can be used until well-defined widely accepted reference AgNP reference materials are available.

NOTE 2 Reference nanoparticle: The reference silver nanoparticle will be introduced by ISO.

NOTE 3 Working nanoparticle: The sample should be analysed.

Annex D (informative)

Silver nanoparticle suspension preparation

The silver nanoparticle powder should be suspended in aqueous (double deionized water) base media (Table 3) in order to perform the interaction of the silver nanoparticles with the bacteria; for homogenization of the suspension, an ultrasonic cleaner (350 W) should be used. After that, the prepared solutions should be added to 25 ml bacterial suspension as well as synthesized AgNPs (5.1.2.6).

In the whole processes, silver nanomaterial only should be used in the 24 h of suspension preparation.

Table D.1 — Treatment conditions, each in triplicate

No. sample	1	2	3	4	5
AgNPs (mg)	0	0,005	0,025	0,05	0,125
Water for suspension (ml)	1,0	1,0	1,0	1,0	1,0
Culture media (1X, ml)	1,5	1,5	1,5	1,5	1,5

NOTE The role of dissolution in silver nanoparticle toxicity is significant. For specific formulations, such as the citrate-capped material, there might be a time-dependency for dissolution that can influence the acceptable product shelf-life.

Annex E (informative)

Treatment control conditions; positive, negative, and bacterial suitability controls

There is no need to carry out the positive/negative controls in the routine analysis. If needed, use the following control substances:

- **Cefixime (as a positive control):** 3 ml of bacterial suspension and 2 ml culture media containing 16 µg/ml cefixime.
- **Negative control:** 3 ml of bacterial suspension and 2 ml culture media.
- **Supernatant control:** The supernatant control is needed in the case of each experiment and related to the sample vehicle. In the case of introduced homemade nanoparticles, it contains: NaNO₃ ($1,0 \times 10^{-3}$ M) aqueous solution containing 0,1 % polyvinyl alcohol (PVA) and 3-sodium citrate (10 %). The treatment is with the same conditions shown in [Table 1](#), including 18 h with shaking.
- **Bacterial suitability control:** A control experiment with fully dissolved silver ion salt (e.g. 0,003 µM AgNO₃, 0,01 µM AgNO₃, 0,03 µM AgNO₃, 0,1 µM AgNO₃, and 3 µM AgNO₃ in culture media) should be performed each time new bacterial cultures are started to ensure that the dose-dependent muramic acid release response to Ag ions is consistent between new bacterial culture preparations. This control establishes that large changes in the bacterial culture and the sensitivity to silver ions have not occurred during expansion of the culture. The silver concentration at which a 50 % relative release in muramic acid occurs should be recorded and used to generate operating specifications for the culture. This EC50 value is nominally approximately 0,9 µM.

Bibliography

- [1] CHEN X., & SCHLUESENER H.J. Nanosilver: a nanoparticle in medical application. *Toxicol. Lett.* 2008, **176** pp. 1–12
- [2] SHRIVASTAVA S., BERA T., ROY A., SINGH G., RAMACHANDRARAO P., DASH D. Characterization of enhanced antimicrobial effects of novel silver nanoparticles. *Nanotechnology*, **18**, 2007 225103 (9 pp)
- [3] ASHARANI P.V., WU Y.L., GONG Z. Valiyaveetil S, Toxicity of silver nanoparticles in zebrafish models. *Nanotechnology*, **19**, 2008 255102 (8 pp)
- [4] ISO 20752, *Cork stoppers — Determination of releasable 2, 4, 6-trichloroanisole (TCA)*
- [5] ISO 8196-1, *Milk – Definition and evaluation of the overall accuracy of alternative methods of milk analysis — Part 1: Analytical attributes of alternative methods*
- [6] ISO/TS 15216-1, *Microbiology of food and animal feed — Horizontal method for determination of hepatitis A virus and norovirus in food using real-time RT-PCR — Part 1: Method for quantification*
- [7] ISO 3534-1, *Statistics – Vocabulary and symbols — Part 1: General statistical terms and terms used in probability*
- [8] VOLLMER W., BLANOT D., de PEDRO M.A. Peptidoglycan structure and architecture. *FEMS Microbiol. Rev.* 2008, **32** pp. 149–167
- [9] ISO/TS 10797, *Nanotechnologies — Characterization of single-wall carbon nanotubes using transmission electron microscopy*
- [10] ISO/TS 80004-6, *Nanotechnologies — Vocabulary — Part 6: Nano-object characterization*
- [11] ZHANG X. Amelung, W. Gas chromatography determination of muramic acid, glucosamine, mannosamine and galactosamine in soils. *Soil Biol. Biochem.* 1996, **28** pp. 1201–1206
- [12] MIRZAJANI F., GHASSEMPOUR A., ALIAHMAD A., ESMAEILI M.A. Antibacterial effect of silver nanoparticles on *Staphylococcus aureus*. *Res. Microbiol.* 2011, **162** pp. 542–549
- [13] LI W.R., XIE X.B., SHI Q.S., ZENG H.Y. OU-Yang, Y.S., Chen, Y.B. Antibacterial activity and mechanism of silver nanoparticles on *Escherichia coli*. *Appl. Microbiol. Biotechnol.* 2010, **85** pp. 1115–1122
- [14] LI W.R., XIE X.B., SHI Q.S., DUAN S.S., OUYANG Y.S., CHEN Y.B. Antibacterial effect of silver nanoparticles on *Staphylococcus aureus*. *Biomedical and Life Science*, 24(1), 2011, pp. 135–141
- [15] JUNG W.K., KOO H.C., KIM K.W., SHIN S., KIM S.H., PARK Y.H. Antibacterial activity and mechanism of action of the silver ion in *Staphylococcus aureus* and *Escherichia coli*. *Appl. Environ. Microbiol.* 2008, **74** (7) pp. 2171–2178
- [16] SONDI I., & SALOPEK-SONDI B. Silver nanoparticle as antimicrobial agent: a case study on *E. coli* as a model for Gram-negative bacteria. *J. Colloid Interface Sci.* 2004, **275** pp. 177–182
- [17] Kozar, M.P., Krahmer, M.T., Fox, A., Lennart, L., Allton, J. Lunar dust: a negative control for biomarker analyses of extraterrestrial samples? *Geochim. Cosmochim. Acta.* 65(19), 2001, pp. 3307–3317.
- [18] Reliability of muramic acid as a bacterial biomarker is influenced by methodological artifacts from streptomycin. *Microb. Ecol.* 2009, **57** (3) pp. 494–500. Available at: Liang, C and Read, H.W and Balsler, T.C
- [19] ISO/TS 12805, *Nanotechnologies — Materials specifications — Guidance on specifying nano-objects.*

- [20] ISO/TR 13014, *Nanotechnologies — Guidance on physico-chemical characterization of engineered nanoscale materials for toxicologic assessment*

British Standards Institution (BSI)

BSI is the national body responsible for preparing British Standards and other standards-related publications, information and services.

BSI is incorporated by Royal Charter. British Standards and other standardization products are published by BSI Standards Limited.

About us

We bring together business, industry, government, consumers, innovators and others to shape their combined experience and expertise into standards-based solutions.

The knowledge embodied in our standards has been carefully assembled in a dependable format and refined through our open consultation process. Organizations of all sizes and across all sectors choose standards to help them achieve their goals.

Information on standards

We can provide you with the knowledge that your organization needs to succeed. Find out more about British Standards by visiting our website at bsigroup.com/standards or contacting our Customer Services team or Knowledge Centre.

Buying standards

You can buy and download PDF versions of BSI publications, including British and adopted European and international standards, through our website at bsigroup.com/shop, where hard copies can also be purchased.

If you need international and foreign standards from other Standards Development Organizations, hard copies can be ordered from our Customer Services team.

Subscriptions

Our range of subscription services are designed to make using standards easier for you. For further information on our subscription products go to bsigroup.com/subscriptions.

With **British Standards Online (BSOL)** you'll have instant access to over 55,000 British and adopted European and international standards from your desktop. It's available 24/7 and is refreshed daily so you'll always be up to date.

You can keep in touch with standards developments and receive substantial discounts on the purchase price of standards, both in single copy and subscription format, by becoming a **BSI Subscribing Member**.

PLUS is an updating service exclusive to BSI Subscribing Members. You will automatically receive the latest hard copy of your standards when they're revised or replaced.

To find out more about becoming a BSI Subscribing Member and the benefits of membership, please visit bsigroup.com/shop.

With a **Multi-User Network Licence (MUNL)** you are able to host standards publications on your intranet. Licences can cover as few or as many users as you wish. With updates supplied as soon as they're available, you can be sure your documentation is current. For further information, email bsmusales@bsigroup.com.

BSI Group Headquarters

389 Chiswick High Road London W4 4AL UK

Revisions

Our British Standards and other publications are updated by amendment or revision.

We continually improve the quality of our products and services to benefit your business. If you find an inaccuracy or ambiguity within a British Standard or other BSI publication please inform the Knowledge Centre.

Copyright

All the data, software and documentation set out in all British Standards and other BSI publications are the property of and copyrighted by BSI, or some person or entity that owns copyright in the information used (such as the international standardization bodies) and has formally licensed such information to BSI for commercial publication and use. Except as permitted under the Copyright, Designs and Patents Act 1988 no extract may be reproduced, stored in a retrieval system or transmitted in any form or by any means – electronic, photocopying, recording or otherwise – without prior written permission from BSI. Details and advice can be obtained from the Copyright & Licensing Department.

Useful Contacts:

Customer Services

Tel: +44 845 086 9001

Email (orders): orders@bsigroup.com

Email (enquiries): cservices@bsigroup.com

Subscriptions

Tel: +44 845 086 9001

Email: subscriptions@bsigroup.com

Knowledge Centre

Tel: +44 20 8996 7004

Email: knowledgecentre@bsigroup.com

Copyright & Licensing

Tel: +44 20 8996 7070

Email: copyright@bsigroup.com



...making excellence a habit.™